A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times ...

The strategy’s top position, healthcare firm Lantheus Holdings LNTH, returned more than 60% as it reported both earnings and revenue well above Wall Street’s expectations. Strong stock ...